Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$27.97 +1.3%	$20.96	$16.10 ▼ $41.94	$3.53B	0.78	3.15 million shs	1.82 million shs
MIRM Mirum Pharmaceuticals	$71.52 +3.6%	$54.81	$36.86 ▼ $72.08	$3.59B	0.94	737,273 shs	1.17 million shs
SRRK Scholar Rock	$35.49 +2.6%	$35.71	$6.76 ▼ $46.98	$3.41B	0.48	1.85 million shs	2.05 million shs
VALN Valneva	$11.64 +4.0%	$7.41	$3.62 ▼ $12.25	$990.49M	1.77	90,346 shs	48,007 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	+1.27%	+0.79%	+40.55%	+60.38%	-29.82%
MIRM Mirum Pharmaceuticals	+3.56%	+5.28%	+34.82%	+62.55%	+73.42%
SRRK Scholar Rock	+2.60%	+12.99%	-10.63%	+18.30%	+283.26%
VALN Valneva	+4.02%	+0.95%	+59.02%	+88.35%	+46.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.1708 of 5 stars	3.3	1.0	4.4	3.5	2.5	0.6
MIRM Mirum Pharmaceuticals	3.4923 of 5 stars	2.6	0.0	4.2	4.1	1.7	0.6
SRRK Scholar Rock	4.5851 of 5 stars	4.6	0.0	4.4	3.0	3.3	0.6
VALN Valneva	2.37 of 5 stars	3.5	3.0	0.0	3.2	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.58	Moderate Buy	$34.12	21.98% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$74.13	3.64% Upside
SRRK Scholar Rock	3.20	Buy	$45.75	28.91% Upside
VALN Valneva	3.00	Buy	$16.00	37.46% Upside

Current Analyst Ratings Breakdown

Latest VALN, APLS, SRRK, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	SRRK Scholar Rock	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$50.00
8/19/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
8/11/2025	MIRM Mirum Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy	$89.00
8/8/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$77.00 ➝ $89.00
8/7/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
8/7/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Outperform ➝ Market Outperform	$79.00 ➝ $81.00
8/7/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$77.00 ➝ $82.00
8/7/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $80.00
8/7/2025	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $45.00
8/4/2025	APLS Apellis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$35.00 ➝ $37.00
8/1/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$17.00 ➝ $19.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	4.52	N/A	N/A	$1.24 per share	22.56
MIRM Mirum Pharmaceuticals	$336.89M	10.67	N/A	N/A	$5.08 per share	14.08
SRRK Scholar Rock	$33.19M	102.79	N/A	N/A	$2.43 per share	14.60
VALN Valneva	$183.52M	5.40	$0.10 per share	119.13	$2.49 per share	4.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	11/4/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.21	N/A	N/A	N/A	-13.65%	-24.76%	-8.50%	11/11/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.91	N/A	N/A	N/A	N/A	-127.11%	-90.09%	11/11/2025 (Estimated)
VALN Valneva	-$13.25M	-$0.98	N/A	N/A	N/A	-33.87%	-34.78%	-13.43%	11/6/2025 (Estimated)

Latest VALN, APLS, SRRK, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	VALN Valneva	-$0.27	-$0.16	+$0.11	-$0.16	$46.28 million	$54.84 million
8/6/2025	Q2 2025	MIRM Mirum Pharmaceuticals	-$0.31	-$0.12	+$0.19	-$0.12	$107.91 million	$127.79 million
8/6/2025	Q2 2025	SRRK Scholar Rock	-$0.66	-$0.98	-$0.32	-$0.98	$0.11 million	N/A
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
MIRM Mirum Pharmaceuticals	1.21	3.13	2.97
SRRK Scholar Rock	0.21	6.33	6.33
VALN Valneva	0.66	2.27	1.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
MIRM Mirum Pharmaceuticals	N/A
SRRK Scholar Rock	91.08%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
MIRM Mirum Pharmaceuticals	14.36%
SRRK Scholar Rock	13.30%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	118.08 million	Optionable
MIRM Mirum Pharmaceuticals	140	50.24 million	43.02 million	Optionable
SRRK Scholar Rock	140	96.13 million	83.34 million	Optionable
VALN Valneva	700	85.09 million	72.41 million	Not Optionable

VALN, APLS, SRRK, and MIRM Headlines

Recent News About These Companies

Valneva suspended from marketing chikungunya shot in U.S. over safety concerns

August 23 at 6:15 PM | msn.com

Q3 Earnings Estimate for Valneva Issued By HC Wainwright

August 23 at 7:28 AM | marketbeat.com

Valneva SE (ADR) trading halted, news pending

August 22 at 12:35 AM | msn.com

Valneva (NASDAQ:VALN) Hits New 52-Week High - Should You Buy?

August 22 at 5:36 AM | marketbeat.com

Valneva (NASDAQ:VALN) Given Buy Rating at HC Wainwright

August 21 at 8:10 AM | marketbeat.com

HC Wainwright Begins Coverage on Valneva (NASDAQ:VALN)

August 21 at 2:37 AM | americanbankingnews.com

Valneva (NASDAQ:VALN) Sees Unusually-High Trading Volume - What's Next?

August 20 at 2:39 PM | marketbeat.com

Valneva’s chikungunya vaccine, Ixchiq receives Health Canada marketing authorization

August 19, 2025 | pharmabiz.comP

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

August 19, 2025 | finance.yahoo.com

Valneva’s Chikungunya Vaccine IXCHIQ® Gains Health Canada Approval

August 19, 2025 | msn.com

Valneva assumed with a Buy at H.C. Wainwright

August 19, 2025 | msn.com

Valneva SE Sponsored ADR (NASDAQ:VALN) Short Interest Update

August 19, 2025 | marketbeat.com

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

August 18, 2025 | globenewswire.com

Valneva (NASDAQ:VALN) Trading 14.3% Higher Following Strong Earnings

August 15, 2025 | marketbeat.com

Valneva (NASDAQ:VALN) Sets New 1-Year High - Time to Buy?

August 15, 2025 | marketbeat.com

A Vaccine for a Mosquito-Borne Disease Fuels Valneva Stock Rally

August 15, 2025 | bloomberg.com

Valneva (NASDAQ:VALN) Shares Gap Up Following Better-Than-Expected Earnings

August 13, 2025 | marketbeat.com

Valneva (NASDAQ:VALN) Announces Quarterly Earnings Results, Beats Estimates By $0.11 EPS

August 13, 2025 | marketbeat.com

Valneva (NASDAQ:VALN) Sees Strong Trading Volume - Time to Buy?

August 12, 2025 | marketbeat.com

Valneva SE 2025 Q2 - Results - Earnings Call Presentation

August 12, 2025 | seekingalpha.com

Valneva Shares Gain After Results, Outlook

August 12, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN, APLS, SRRK, and MIRM Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$27.97 +0.35 (+1.27%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$27.92 -0.04 (-0.16%)

As of 08/22/2025 06:44 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Mirum Pharmaceuticals NASDAQ:MIRM

$71.52 +2.46 (+3.56%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$71.87 +0.35 (+0.49%)

As of 08/22/2025 07:49 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Scholar Rock NASDAQ:SRRK

$35.49 +0.90 (+2.60%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$35.70 +0.20 (+0.58%)

As of 08/22/2025 06:56 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Valneva NASDAQ:VALN

$11.64 +0.45 (+4.02%)

As of 08/22/2025 02:47 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time